An observational study in Pancreatic Fibrosis, sponsored by Moscow Clinical Scientific Center. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-03-20.
Sponsored by Moscow Clinical Scientific Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In chronic pancreatitis, pancreatic fibrosis impairs the ducts patency and secretion and contributes to chronic pain. Another complication of long CP presence is pancreatic exocrine insufficiency (PEI) that is present in 30-90% of patients with CP. Currently, there are no reliable techniques for non-invasive assessment of the pancreatic fibrosis degree. The only accurate method for determining the severity of fibrotic changes in the pancreas is histological examination. Despite the high informativeness of this method, its use is limited by the necessity to obtain biopsy specimens of sufficient diagnostic volume or surgical material, which is associated with the complications risk of an invasive procedure. This makes it impossible to assess the degree of fibrosis in all the patients with pancreatic diseases.
It is possible to overcome the limitations by applying non-invasive diagnostic techniques, the development and grounding of which is planned within the framework of the Project.
Hypothesis The degree of fibrotic changes according to the histological examination can be comparable to the degree of fibrosis of the pancreas identified by non-invasive radiology and laboratory diagnostic methods.
Aim To identify the relationship between the degree of fibrosis in the pancreas assessed by the histological examination and a complex of non-invasive radiology and laboratory diagnostic procedures.
Materials and methods Study design Prospective single-center observational study Inclusion Criteria
Variables
The following parameters will be registered in the case report form (CRF) of the patient:
in CP:
functional activity of the pancreas:
for proximal resections:
for distal resections:
--- Preoperative distal fistula risk score (D-FRS) [16]
surgery and intraoperative parameters:
subjective assessment of pancreatic density by the surgeon
during the formation of pancreatoenteroanastomosis:
for distal resection:
postoperative complications
repeated interventions
--- intervention type
Study design After signing the informed consent, past medical history data, blood, and stool tests will be collected. Multi-slice computed tomography (CT) with intravenous bolus injection of a contrast agent should be performed on an Aquilion CXL 128, 128-row CT scanner with a reconstruction algorithm with a slice thickness of 1 mm and a reconstruction step of 1 mm using non-ionic radiopaque agents with an iodine content of 370 mg/ml or 350 mg/ml. Radiopaque agents will be administered at a rate of 3.5 ml/sec, in a volume of up to 100 ml, depending on the patient's body weight. The CT examination will be carried out as standard; it is a multiphase protocol that includes non-contrast study, arterial, late arterial or pancreatic, venous, and delayed phases, with standard time distribution.
Non-invasive diagnosis of pancreatic fibrosis will be performed by assessing the contrast ratio based on sequential densitometry of the head, body and tail of the pancreas and blood in the aorta at the level of the pancreas. X-ray density measurements will be carried out in the native, late arterial, and venous phases.
X-ray density will be measured in Hounsfield units in a limited area of 0.2-0.8 cm2. The results for individual areas of the pancreas in each patient with this technique will be summarized as means and medians. The measurements will be taken by an abdominal CT radiologist with more than 5 years of experience.
In addition, a non-invasive assessment of the microvasculature based on the calculation of the median of the contrast gradient is planned to apply for patients with a need for differential diagnosis. Calculations will also be carried out based on the results of CT.
For accurate mapping of findings in the pancreas, dissection of the samples will be carried out with mandatory photo fixation. The dissection of the organ complex will be conducted according to the technique described by O.V. Paklina and G.R. Setdikova depending on the neoplastic process location. [21]
For the study, several sections of the pancreas will be studied:
All samples will be taken into different cassettes with precise labeling and fixation on a macro photo. The material will be fixed in a 10% buffered formalin solution, then carried out according to the standard method. Serial 3 µm thick paraffin sections will be stained with hematoxylin and eosin.
The degree of fibrotic changes will be assessed in points separately for intra- and perilobular fibrosis. Changes in the ductal system, the presence of inflammatory elements, and their severity (scattered, nodular, etc.), changes in the vascular bed and nerve trunks will also be evaluated.
Statistical data analysis Evaluation of quantitative parameters for compliance with the normal distribution will be performed using the Shapiro-Wilk test.
For describing quantitative parameters that have a normal distribution, the obtained data are combined into variational series in which the calculation of arithmetic means (M) and standard deviations (SD), borders of the 95% confidence interval (95% CI) will be carried out.
Sets of quantitative indicators, the distribution of which differs from the normal, will be described using the values of the median (Me) and the lower and upper quartiles (Q1-Q3). Nominal parameters will be described with absolute values and percentages.
When comparing means in normally distributed populations of quantitative data, Student's t-test will be calculated. The acquired Student's t-test values will be evaluated by comparison with critical values. Differences in parameters will be considered statistically significant at a significance level of p\<0.05.
To compare independent populations in cases with no signs of a normal distribution, the Mann-Whitney U-test will be used.
Comparison of nominal data is carried out using Pearson's χ2 test, which allows assessing the significance of differences between the actual number of outcomes or qualitative characteristics of the sample falling into each category and the theoretical number that can be expected in the studied groups if the null hypothesis is true.
The Wilcoxon W-test will be used to analyze differences between two compared paired samples. In this case, the value of the parameter change will be calculated for each patient.
In order to study the relationship between phenomena represented by quantitative data, the distribution of which differed from normal, a non-parametric Spearman rank correlation coefficient method will be used.
As a quantitative measure of the effect when comparing relative indicators, the odds ratio (OR) will be used, defined as the ratio of the probability of an event occurring in a group exposed to a risk factor to the probability of an event occurring in a control group. The odds ratio is calculated based on the resulting contingency tables.
Moscow Clinical Scientific Center is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
adult patients with pre-planned pancreatic resection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
correlation between non-invasive and invasive markers of pancreatic fibrosis
fibrotic changes according to the histological examination can be comparable to the degree of fibrosis of the pancreas identified by non-invasive radiology and laboratory diagnostic methods
Time frame: 3 years
Plan to share: Undecided
Started Jul 2022 (actual). Primary completion is estimated for Jul 2025, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Moscow Clinical Scientific Center